Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 11Rituximab 6Prednisone 6fludarabine 5Vincristine 5Doxorubicin 5Etoposide 4fludarabine phosphate 3Bortezomib 3Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2MLN 8237 2Electrocardiography 2Echocardiography 2Diphenhydramine 2CT-P10 2Automobiles 2Acetaminophen 2venetoclax 1varlilumab 1tositumomab I-131 1tazemetostat 1saponin QA-21V1 1romidepsin 1pomalidomide 1obinutuzumab 1molibresib 1magrolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell × Maraviroc × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡